The overlap between trauma &amp; disruptive behavior disorders

Menand, Emily; Cox, Lara Jo

doi:10.1016/b978-0-12-818954-2.00033-x

Cited by 2 publications

(1 citation statement)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…That is, the effect of location appeared to be driven by greater racial/ethnic minority sample composition in US-based studies. These findings reinforce calls to develop culturally informed DBD treatments and measures of CU traits (Johnson, Anhalt, & Cowan, 2018;Taylor & Ray, 2021), as well as to address racism experienced by historically marginalized racial/ethnic groups within healthcare settings (Mateo & Williams, 2021), which impacts diagnosis, conceptualization of risk factors, and treatments for DBD (Fadus et al, 2020;Menand & Cox, 2022).…”

Section: Discussionsupporting

confidence: 55%

Treatment of childhood disruptive behavior disorders and callous‐unemotional traits: a systematic review and two multilevel meta‐analyses

Perlstein

Fair

Hong

et al. 2023

Child Psychology Psychiatry

View full text Add to dashboard Cite

Background Children with callous‐unemotional (CU) traits are at high lifetime risk of antisocial behavior. It is unknown if treatments for disruptive behavior disorders are as effective for children with CU traits (DBD+CU) as those without (DBD‐only), nor if treatments directly reduce CU traits. Separate multilevel meta‐analyses were conducted to compare treatment effects on DBD symptoms for DBD+CU versus DBD‐only children and evaluate direct treatment‐related reductions in CU traits, as well as to examine moderating factors for both questions. Methods We systematically searched PsycINFO, PubMed, Cochran Library (Trials), EMBASE, MEDLINE, APA PsycNet, Scopus, and Web of Science. Eligible studies were randomized controlled trials, controlled trials, and uncontrolled studies evaluating child‐focused, parenting‐focused, pharmacological, family‐focused, or multimodal treatments. Results Sixty studies with 9,405 participants were included (Mage = 10.04, SDage = 3.89 years, 25.09% female, 44.10% racial/ethnic minority). First, treatment was associated with similar reductions in DBD symptoms for DBD+CU (SMD = 1.08, 95% CI = 0.45, 1.72) and DBD‐only (SMD = 1.01, 95% CI = 0.38, 1.64). However, DBD+CU started (SMD = 1.18, 95% CI = 0.57, 1.80) and ended (SMD = 0.73, p < .001; 95% CI = 0.43, 1.04) treatment with more DBD symptoms. Second, although there was no overall direct effect of treatment on CU traits (SMD = .09, 95% CI = −0.02, 0.20), there were moderating factors. Significant treatment‐related reductions in CU traits were found for studies testing parenting‐focused components (SMD = 0.21, 95% CI = 0.06, 0.35), using parent‐reported measures (SMD = 0.16, 95% CI = 0.04, 0.28), rated as higher quality (SMD = 0.26, 95% CI = 0.13, 0.39), conducted outside the United States (SMD = 0.19, 95% CI = 0.05, 0.32), and with less than half the sample from a racial/ethnic minority group (SMD = 0.15, 95% CI = 0.002, 0.30). Conclusions DBD+CU children improve with treatment, but their greater DBD symptom severity requires specialized treatment modules that could be implemented alongside parenting programs. Conclusions are tempered by heterogeneity across studies and scant evidence from randomized controlled trials.

show abstract